Skip to main content
. 2020 Jan 30;11:619. doi: 10.1038/s41467-020-14373-2

Table 1.

Demographics and biomarkers data from the different cohorts.

n Age Sex (f/m) t-Tau (pg/mL) p-Tau (pg/mL) Amyloid β42 (pg/mL) Lipocalin 2 (pg/mL)
Cohort 1
ND 73 67 ± 10 40/33 232 ± 207 40 ± 11 719 ± 351 771 ± 347
AD 47 67 ± 10 26/21 591 ± 435 90 ± 51 449 ± 207 691 ± 247
VaD 27 72 ± 8 17/10 386 ± 445 44 ± 15 779 ± 348 2233 ± 1326
MD 31 74 ± 10 25/6 444 ± 272 76 ± 54 437 ± 206 1565 ± 833
LBD 36 69 ± 11 18/18 385 ± 301 56 ± 42 513 ± 292 917 ± 398
FTD 21 65 ± 12 8/13 373 ± 370 57 ± 21 665 ± 251 762 ± 331
CJD 54 68 ± 10 27/27 5936 ± 5914 61 ± 18 635 ± 324 1037 ± 661
SVDND 20 63 ± 14 9/11 181 ± 135 34 ± 16 787 ± 229 753 ± 300
VCIND 7 66 ± 9 2/5 177 ± 59 48 ± 12 1114 ± 220 946 ± 366
Cohort 2
ND 24 64 ± 8 12/12 168 ± 74 35 ± 14 913 ± 409 713 ± 232
AD 15 68 ± 6 6/9 602 ± 336 71 ± 27 417 ± 95 660 ± 182
VaD 10 69 ± 10 3/7 330 ± 236 38 ± 13 768 ± 188 1440 ± 979
Cohort 3
ND 15 67 ± 13 7/8 193 ± 57 33 ± 9 684 ± 123 753 ± 386
AD 27 72 ± 6 16/11 647 ± 307 88 ± 29 435 ± 81 709 ± 236
VaD 16 74 ± 6 10/6 402 ± 300 55 ± 23 501 ± 134 1381 ± 953
Cohort 4
AD 28 72 ± 10 21/7 595 ± 234 86 ± 25 634 ± 228 634 ± 198
SVDND 3 71 ± 8 1/2 135 ± 37 27 ± 9 953 ± 55 613 ± 258
VCIND 8 67 ± 5 3/5 174 ± 45 38 ± 12 869 ± 328 845 ± 277
VaD 10 76 ± 6 3/7 248 ± 66 43 ± 11 932 ± 221 1131 ± 481

Number of cases (n), age (mean ± standard deviation), sex (female/male), CSF biomarkers total-Tau, p-Tau and amyloid beta 42 and CSF LCN2 (mean ± standard deviation in pg/mL) are indicated.

ND non-primarily neurodegenerative and non-ischemic neuropsychiatric diseases, AD Alzheimer’s disease, VaD vascular dementia, MD mixed dementia, LBD Lewy body dementia, FTD frontotemporal dementia, CJD sporadic Creutzfeldt-Jakob disease, SVDND small vessel disease no dementia, VCIND vascular cognitive impairment no dementia.